Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer:: An international phase II study.

被引：0
|
作者：
Rubio, ED
Tabernero, J
van Cutsem, E
Cervantes, A
André, T
Humblet, Y
Soulié, P
Corretgé, S
Kisker, O
de Gramont, A
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Univ Vall Hebron, Barcelona, Spain
[3] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[4] Hosp Clin Univ, Valencia, Spain
[5] Hop Tenon, F-75970 Paris, France
[6] Clin Univ St Luc, Brussels, Belgium
[7] Ctr Paul Papin, Angers, France
[8] Merck Farma & Quim, Barcelona, Spain
[9] Merck KGaA, Darmstadt, Germany
[10] Hop St Antoine, F-75571 Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：254S / 254S
页数：1
相关论文
共 50 条
  • [1] An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR)
    Van Cutsem, Eric J. D.
    Tabemero, J.
    Diaz-Rubio, E.
    Chirivella, I.
    Andre, T.
    Humblet, Y.
    Van Laethem, J-L
    Kisker, O.
    Farres, J.
    de Gramont, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 91 - 91
  • [2] An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR).: Preliminary results.
    Tabernero, JM
    Van Cutsem, E
    Sastre, J
    Cervantes, A
    Van Laethem, JL
    Humblet, Y
    Soulié, P
    Corretgé, S
    Mueser, M
    De Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 248S - 248S
  • [3] Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting:: a phase II study
    Cervantes, A.
    Casac, E.
    Van Cutsem, E.
    Sastre, J.
    Andre, T.
    Humblet, Y.
    Van Laethem, J.
    Zubel, A.
    Gascon, N.
    de Gramont, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 181 - 182
  • [4] Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)
    Folprecht, G.
    Lutz, M. P.
    Schoeffski, P.
    Seufferlein, T.
    Nolting, A.
    Pollert, P.
    Koehne, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 199
  • [5] A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results
    Hoehler, Thomas
    Dittrich, Christian
    Lordick, Florian
    Seufferlein, Thomas
    Riemann, Juergen F.
    Woell, Ewald
    Herrmann, Thomas
    Olchowka, Klaudia
    Kisker, Oliver
    Schmoll, Hans-Joachim
    ANNALS OF ONCOLOGY, 2004, 15 : 69 - 70
  • [6] Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
    Folprecht, G
    Lutz, MP
    Schöffski, P
    Seufferlein, T
    Nolting, A
    Pollert, P
    Köhne, CH
    ANNALS OF ONCOLOGY, 2006, 17 (03) : 450 - 456
  • [7] A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results.
    Seufferlein, T
    Dittrich, C
    Riemann, J
    Woell, E
    Herrmann, T
    Lordick, F
    Arnold, D
    Olchowka, K
    Hoehler, T
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 281S - 281S
  • [8] Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study
    Bokemeyer, C.
    Bondarenko, I.
    Makhson, A.
    Hartmann, J. T.
    Aparicio, J.
    Zampino, M.
    Donea, S.
    Ludwig, H.
    Zubel, A.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Peeters, M.
    Raoul, J.-L.
    Van Laethem, J.-L.
    Rougier, P.
    Brezault, C.
    Husseini, F.
    Cals, L.
    Zubel, A.
    Vedovato, J.-C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 188 - 188
  • [10] FIRST LINE CHEMOTHERAPY (FLC) USING OXALIPLATIN, 5-FLUOROURACIL (5-FU) AND FOLINIC ACID (FA) (FOLFOX-4) COMBINED WITH BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC)
    Gluzman, A.
    Fridman, J.
    Lazarev, I
    Man, S.
    Walfish, S.
    Ariad, S.
    Lavrenkov, K.
    ANNALS OF ONCOLOGY, 2009, 20 : 66 - 66
12345